Am J Transplant, Volume 17, Suppl 3 Archives - Page 16 of 181 - ATC Abstracts

2017 American Transplant Congress
The Impact of De Novo Post-Transplant Diabetes on Hepatic Steatosis and Liver Transplant Outcomes.
C. Reuter,¹ R.-A. Lee,¹ R. Watkins,³ S. Lieber,² K. Szempruch,¹ D. Gerber,⁴ G. DeCherney,² A. Barritt IV.²
¹Department of Pharmacy, UNC Health Care, Chapel Hill, NC; ²Department of Medicine, UNC Health Care, Chapel Hill, NC; ³UNC Center for Transplant Care, UNC Health Care, Chapel Hill, NC; ⁴Department of Surgery, UNC Health Care, Chapel Hill, NC
Introduction: As the prevalence of diabetes (DM) increases in the general population, it is also increasing in the transplant (Tx) population. Post-transplant diabetes (PTDM) has…
2017 American Transplant Congress
Limited Impact of Pre-Existing Donor Specific HLA Antibodies on Long Term Survival After First Adult Liver Transplantation.
M. Koch,¹ M. Marget,² M. Sterneck,³ H. Thude,¹ B. Nashan.¹
¹Hepatobiliary Surgery and Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany; ²Transfusion Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany; ³Internal Medicine I, Gastroenterology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Donor specific antibodies (DSA) are known to play a pivotal role in long term kidney allograft survival. Their importance in liver transplanted patients (LTX) is…
2017 American Transplant Congress
Donor and Recipient Factors Important in Determining the Estimated GFR Difference Between Living Donor and Recipient Pairs Six Months After Transplant.
D. Keith.
Medicine, Division of Nephrology, Sacred Heart Hospital, Pensacola, FL
Analysis of the relationship between living donor and recipient estimated GFR (eGFR) six months after transplant revealed that in the first half of the last…
2017 American Transplant Congress
How Potential Living Kidney Donors (LKDs) View ESRD Risk: A Multi-Center Study.
C. Thiessen,¹ G. Gannon,¹ D. Gray,² K. Kennedy,³ D. Dobosz,¹ S. Li,¹ K. Yu,¹ A. Mussell,² E. Gordon,³ P. Reese,² S. Kulkarni.¹
¹Yale U, New Haven; ²U Pennsylvania, Philadelphia; ³Northwestern U, Chicago
PurposeTo determine how kidney donors view ESRD risk at initial donor evaluation.MethodsWe conducted a longitudinal, prospective study of LKDs at three centers and report results…
2017 American Transplant Congress
Impact of Type of Kidney (Living vs. Deceased) on Urinary Podocyte Excretion Rate in Renal Allografts.
A. Naik, D. Luan, D. Cibrik, M. Samaniego, K. Woodside, M. Chowdhury, S. Wang, R. Wiggins.
U Michigan, Ann Arbor
Aim: Long term allograft survival has not improved.Surveillance biopsy studies have demonstrated that chronic microcirculatory injury and progressive glomerulosclerosis are the most common histological finding…
2017 American Transplant Congress
A Thirteen-Year Mayo Clinic Retrospective Study of the Syndrome of Rapid Onset ESRD Among Renal Transplant Recipients, 2001-2013.
M. Onuigbo,^1,2 N. Agbasi.³
¹Medicine, Mayo Clinic, Rochester, MN; ²Nephrology, Mayo Clinic Health System, Eau Claire, WI; ³Mental Health, North East London NHS Foundation Trust, Ilford, Essex, United Kingdom
Introduction: We described the syndrome of rapid onset ESRD (SORO-ESRD), acute yet irreversible renal failure, for the first time in the journal Renal Failure in…
2017 American Transplant Congress
Hurdles to Broader Implementation of the A₂/A₂BàB Deceased Donor Kidney Allocation Provision.
I. Kim,¹ A. Wilk,² A. Robinson,² P. Martins,³ V. Whitaker,⁴ E. Ward,² C. Miles.⁵
¹Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA; ²United Network for Organ Sharing, Richmond, VA; ³Department of Surgery, University of Massachusetts, Worcester, MA; ⁴Department of Surgery, State University of New York, Syracuse, NY; ⁵Department of Medicine, University of Nebraska Medical Center, Omaha, NE
Background: A2/A2B to blood group B kidney transplantation has improved transplant rates among disadvantaged blood group B patients with equivalent long-term graft outcomes. 18 months…
2017 American Transplant Congress
Manning the Gap: Using Technology to Reduce Barriers in Access to Renal Transplantation Waiting List Across Dialysis Facilities.
G. Ferreira,¹ K. Bastos,² E. Barbeta,² B. Pereira,² G. Souza,¹ M. de Souza,¹ V. Colares.¹
¹Kideny Transplant UPI, Santa Casa de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil; ²Nephrology, CTDR, Juiz de Fora, Minas Gerais, Brazil
Background:Pervasive disparities in access to kidney transplantation persist despite decades of recognition and efforts to improve equity in transplant access. Using technology to reduce the…
2017 American Transplant Congress
Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients.
M. Marron-Wojewodzki,¹ I. Szwarc,¹ C. Rene,² G. Mourad,¹ M. Le Quintrec.^1,3
¹Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier, France; ²Departement of Immunology, Hôpital Saint Eloi, Montpellier, France; ³Inserm U1183,, IRMB,Hôpital Saint Eloi, Montpellier, France
Background.Development of de novo donor specific antibodies (dnDSA) concerns about 10% of patients within the first year following kidney transplantation and reach about 20% within…
2017 American Transplant Congress
Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).
C. Danthu,¹ M. Gomes-Mayeras,¹ D. Andouard,² E. Munteanu,¹ R. Moulinas,^1,4 G. Ligat,² S. Hantz,^1,2 J. Rerolle,³ F. Garnier,¹ M. Essig,³ S. Alain.^1,2,4
¹National Reference Center for CMV-Virology, CHU Limoges, Limoges, France; ²UMR Inserm 1092, Université Limoges, Limoges, France; ³Nephrology, CHU Limoges, Limoges, France; ⁴GenoLim/Biscem Genomic Platform, Université Limoges, Limoges, France
Results from the French Cohorts 2006-2010 and OrphaVic (NCTNCT02067169) indicates that fifty percent of graft failures in renal recipients infected by HCMV after treatment with…